Skip to main content

At Verily, a growing line of business builds on a revolving door to the FDA

By STAT News  
   October 05, 2022

The Alphabet life sciences spinout is doubling down on the business of evidence generation, trying to build the tools and technical infrastructure that will help pharma and digital health customers run the next generation of clinical trials.

Full story

Get the latest on healthcare leadership in your inbox.